In an editorial accompanying the study, Dr. Khosla noted that 15 months of the higher-dose therapy would cost $76,000, which would be expected to decline after teriparatide went off patent in August 2019, “although considering recent trends in generic drug pricing, a price decrease is by no means certain.”2
The National Institutes of Health and the Dart Foundation funded the research.
- Tsai JN, Lee H, David NL, et al. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): A randomized, controlled phase 4 trial. Lancet Diabetes Endocrinol. 2019 Aug 22. pii: S2213-8587(19)30255-4. [Epub ahead of print]
- Khosla S. Personalizing osteoporosis treatment for patients at high risk of fracture. Lancet Diabetes Endocrinol. 2019 Aug 22. pii: S2213-8587(19)30266-9. [Epub ahead of print]